Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $56.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $56.57.

AGIO has been the subject of a number of research reports. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Royal Bank of Canada boosted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Erste Asset Management GmbH purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $97,199,000. Jefferies Financial Group Inc. purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $49,290,000. Vestal Point Capital LP purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $33,767,000. Adage Capital Partners GP L.L.C. purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $9,957,000. Finally, Paradigm Biocapital Advisors LP purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $9,084,000.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $35.54 on Monday. Agios Pharmaceuticals has a 1-year low of $27.14 and a 1-year high of $62.58. The business has a fifty day moving average price of $33.89 and a 200-day moving average price of $42.73. The stock has a market capitalization of $2.04 billion, a P/E ratio of 3.13 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts anticipate that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.